This invention pertains to certain active carbamic acid compounds which inhibit
HDAC activity and which have the following formula: (I) A is an aryl group; Q1
is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected
from: S(O)2NR1 and NR1S(O)2;
R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with
the proviso that if J is S(O)2NR1,
then Q1 is an aryl leader group; and pharmaceutically acceptable salts,
solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof.
The present invention also pertains to pharmaceutical compositions comprising such
compounds, and the use of such compounds and compositions, both in vitro and in
vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as
cancer and psoriasis.
##STR1##
